GLP-1 analogues in treatment of type 1 diabetes mellitus;GLP-1-Analoga in der Therapie des Diabetes mellitus Typ 1

Deutsche Medizinische Wochenschrift

Volumn 139, Issue 42, 2014, Pages 2123-2126

  Tolle S ^a  

^a Diabetes Adipositas Zentrum Zürich   (Switzerland)

Author keywords

GLP 1 analogues; glycemic control; treatment; type 1 diabetes mellitus

Indexed keywords

GLUCAGON; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; INSULIN; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL;

ARTICLE; CLINICAL TRIAL (TOPIC); DIABETIC PATIENT; DRUG DOSE REDUCTION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; ANALOGS AND DERIVATIVES; BLOOD; DIABETES MELLITUS, TYPE 1; DRUG COMBINATION; EVIDENCE BASED MEDICINE; META ANALYSIS; METABOLISM; TREATMENT OUTCOME;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; TREATMENT OUTCOME;

EID: 84921721458     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0034-1387304     Document Type: Article

References (15)

1. Drucker D. J., Nauck M. A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet: 2006; 368 1696 1705
2. Dupre J. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans. Regul Pept: 2006; 15 149 157
3. Issa C. M., Azar S. T. Possible role of GLP-1 and its agonists in the treatment of type 1 diabetes mellitus. Curr Diab Rep: 2012; 12 560 567
4. Kielgast U. et al. Effect of glucagon-like peptide-1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients. J Clin Endocrinol and Metab: 2010; 95 2492 2496
5. Kielgast U., Holst J. J., Madsbad S. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function. Diabetes: 2011; 60 1599 1607
6. Kielgast U., Holst J. J., Madsbad S. Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists. Curr Diabetes Rev: 2009; 5 266 275
7. Kielgast U. et al. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care: 2011; 34 1463 1468
8. Knudsen B. et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology: 2010; 151 1473 1486
9. Raman V. S., Heptulla R. A. New potential adjuncts to treatment of children with type 1 diabetes mellitus. Pediatr Research: 2009; 65 370 374
10. Raman V. S. et al. The Role of Adjunctive Exenatide Therapy in Pediatric Type 1 Diabetes. Diabetes Care: 2010; 33 1294 1296
11. Tamborlane W. V. et al. Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes. N Engl J Med: 2008; 359 1464 1476
12. Vangoitsenhoven R., Mathieu C., Van der Schueren B. GLP1 and cancer: friend or foe. Endocr Relat Cancer: 2012; 1 77 88
13. Varanasi A. et al. Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol: 2011; 165 77 84
14. Varga T. et al. Elevated serum DPP4 activity in type 1 diabetes mellitus: a direct comparison. Orvi Hetil: 2010; 151 899 902
15. Kruszynska Y. T. Normal metabolism: the physiology of fuel homeostasis. In: Williams G., Pickup J. C., Hrsg. Textbook of Diabetes. 2nd ed. Boston Blackwell Science; 1997; 111 121